Moracin M derivative targeting PDE4 for the treatment of psoriasis

Abstract

Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase superfamily, has highly important roles in cyclic nucleotide signaling pathways and a variety of skin disorders. Blocking PDE4 activity with PDE4 inhibitors increases intracellular cAMP levels and effectively relieves the skin inflammatory phenotype of psoriasis. However, traditional PDE4 inhibitors may cause adverse effects such as gastrointestinal reactions. Natural products typically exhibit safety profiles and structural novelty, which are particularly advantageous for drug discovery. LW, a derivative of the natural product Moracin M, was found to have favorable PDE4 inhibitory activity (PDE4 IC₅₀ = 54 nM). Examination of LW in psoriasis treatment demonstrated good anti-inflammatory effects in cellular models. In an imiquimod-induced mouse model, LW treatment markedly improved psoriatic symptoms, as evidenced by increased PASI scores and ameliorated skin pathology. Moreover, LW significantly downregulated Inflammatory factors in the serum and alleviated spleen damage. Therefore, LW has substantial therapeutic potential, through effectively decreasing inflammatory factor levels and ameliorating psoriatic skin phenotypes. Our findings support LW as a potential candidate compound for developing new psoriasis treatments.

Keywords

Moracin M / PDE4 inhibitor / psoriasis / inflammatory factor

References

[1] Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J: Psoriasis. Lancet (London, England) 2021, 397: 1301-1315.

[2] Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D: Targeting IL-23 in Psoriasis: Current Perspectives. Psoriasis (Auckland, N.Z.) 2018, 8: 1-5.

[3] Ghoreschi K, Balato A, Enerbäck C, Sabat R: Therapeutics Targeting the IL-23 and IL-17 Pathway in Psoriasis. Lancet (London, England) 2021, 397: 754-766.

[4] Wu Y, Li Z, Huang YY, Wu D, Luo HB: Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease. Journal of Medicinal Chemistry 2018, 61: 5467-5483.

[5] Dastidar SG, Rajagopal D, Ray A: Therapeutic Benefit of PDE4 Inhibitors in Inflammatory Diseases. Current Opinion in Investigational Drugs 2007, 8: 364-372.

[6] Sakkas LI, Mavropoulos A, Bogdanos DP: Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives. Current Medicinal Chemistry 2017, 24: 3054-3067.

[7] Gooderham M, Papp K: Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. BioDrugs 2015, 29: 327-339.

[8] Li H, Zuo J, Tang W: Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology 2018, 9: 1048.

[9] Gianello V, Salvi V, Parola C, Moretto N, Facchinetti F, Civelli M, et al.: The PDE4 Inhibitor CHF6001 Modulates Pro-inflammatory Cytokines, Chemokines and Th1- and Th17-Polarizing Cytokines in Human Dendritic Cells. Biochemical Pharmacology 2019, 163: 371-380.

[10] Cao M, Nawalaniec K, Ajay AK, Luo Y, Moench R, Jin Y, et al.: PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner. Translational oncology 2022, 19: 101377.

[11] Kim JJ, Kim DH, Lee JY, Lee BC, Kang I, Kook MG, et al.: cAMP/EPAC Signaling Enables ETV2 to Induce Endothelial Cells with High Angiogenesis Potential. Molecular Therapy 2020, 28: 466-478.

[12] Li H, Li J, Zhang X, Feng C, Fan C, Yang X, et al.: DC591017, a Phosphodiesterase-4 (PDE4) Inhibitor with Robust Anti-inflammation Through Regulating PKA-CREB Signaling. Biochemical Pharmacology 2020, 177: 113958.

[13] Lebwohl MG, Papp KA, Stein Gold L, Gooderham MJ, Kircik LH, Draelos ZD, et al.: Trial of Roflumilast Cream for Chronic Plaque Psoriasis. The New England Journal of Medicine 2020, 383: 229-239.

[14] Woodby B, Sticozzi C, Pambianchi E, Villetti G, Civelli M, Valacchi G, et al.: The PDE4 Inhibitor CHF6001 Affects Keratinocyte Proliferation via Cellular Redox Pathways. Archives of Biochemistry and Biophysics 2020, 685: 108355.

[15] Bhat A, Ray B, Mahalakshmi AM, Tuladhar S, Nandakumar DN, Srinivasan M, et al.: Phosphodiesterase-4 Enzyme as a Therapeutic Target in Neurological Disorders. Pharmacological Research 2020, 160: 105078.

[16] Warren RB, French LE, Blauvelt A, Langley RG, Egeberg A, Mrowietz U, et al.: Orismilast in Moderate-to-Severe Psoriasis: Efficacy and Safety from a 16-Week, Randomized, Double-blinded, Placebo-controlled, Dose-finding, and Phase 2b trial (IASOS). Journal of the American Academy of Dermatology 2024, 90: 494-503.

[17] Heckman PR, Blokland A, Ramaekers J, Prickaerts J: PDE and Cognitive Processing: Beyond the Memory Domain. Neurobiology of Learning and Memory 2015, 119: 108-122.

[18] Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al.: Apremilast, an Oral Phosphodiesterase 4 (PDE4) Inhibitor, in Patients with Moderate to Severe Plaque Psoriasis: Results of a Phase III, Randomized, Controlled Trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Journal of the American Academy of Dermatology 2015, 73: 37-49.

[19] Xu N, Gao Z, Wu D, Chen H, Zhang Z, Zhang L, et al.: 5-Hydroxymethylcytosine Features of Portal Venous Blood Predict Metachronous Liver Metastases of Colorectal Cancer and Reveal Phosphodiesterase 4 as a Therapeutic Target. Clinical and Translational Medicine 2025, 15: e70189.

[20] Song Z, Huang YY, Hou KQ, Liu L, Zhou F, Huang Y, et al.: Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis. Journal of Medicinal Chemistry 2022, 65: 4238-4254.

[21] Shou Y, Yang L, Yang Y, Xu J: Inhibition of Keratinocyte Ferroptosis Suppresses Psoriatic Inflammation. Cell Death & Disease 2021, 12: 1009.

[22] Chiricozzi A, Caposiena D, Garofalo V, Cannizzaro MV, Chimenti S, Saraceno R: A New Therapeutic for the Treatment of Moderate-to-Severe Plaque Psoriasis: Apremilast. Expert Review of Clinical Immunology 2016, 12: 237-249.

[23] Gupta RK, Gracias DT, Figueroa DS, Miki H, Miller J, Fung K, et al.: TWEAK Functions with TNF and IL-17 on Keratinocytes and is a Potential Target for Psoriasis Therapy. Science Immunology 2021, 6: eabi8823.

[24] Milakovic M, Gooderham MJ: Phosphodiesterase-4 Inhibition in Psoriasis. Psoriasis (Auckland, N.Z.) 2021, 11: 21-29.